Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Method Described for Blocking Action of Cancer-Promoting MicroRNA

By LabMedica International staff writers
Posted on 08 Aug 2016
A team of molecular biologists has described a novel method for selectively blocking the activity of a cancer-promoting microRNA.

MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. More...
Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

In order to block the activity of the miRNA miR-21, which is present in high levels in many tumors where it increases the expression of cancer-promoting genes and decreases cancer suppressors, investigators at the University of Washington (Seattle, USA) manipulated the specificity of the RNA recognition motif (RRM) of the protein Rbfox2 (RNA binding protein, fox-1 homolog 2). They did this by engineering the conserved RRM of the Rbfox2 protein to specifically bind to the terminal loop of the microRNA precursor (pre-miR-21) with high affinity.

The modified pre-miR-21 could not be processed by the enzyme Dicer. Dicer, which is encoded by the DICER1 gene, trims double stranded RNA, to form small interfering RNA (siRNA) or microRNA (miRNA). These processed RNAs are incorporated into the RNA-induced silencing complex (RISC), which targets messenger RNA to prevent translation.

In a separate series of experiments the investigators attached the miR-21 binding regions of Rbfox2 onto the Dicer enzyme. This hybrid Rbfox2-Dicer protein sliced miR-21 into inactive fragments. Results published in the July 18, 2016, online edition of the journal Nature Chemical Biology revealed that the hybrid enzyme degraded pre-miR-21 specifically in vitro and suppressed mature miR-21 levels in cells, which resulted in increased expression of the tumor suppressor PDCD4 and significantly decreased viability for cancer cells.

"What we show here is a proving ground - a process to determine how to make the correct changes to proteins," said senior author Dr. Gabriele Varani, professor of chemistry at the University of Washington. "This method relies on knowledge of high-quality structures. That allowed us to see which alterations would change binding to the microRNA target."

Related Links:
University of Washington



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Four-quadrant streaking of fecal samples on chromogenic UTI agar shows various patterns of relative bacterial species abundance. The assorted shapes of the pinkish colonies indicate different E. coli strains. (Photo courtesy of Sokurenko Lab)

Stool Testing Predicts UTI Risk and Guides Antibiotic Selection

Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.